Michael T Davis
Overview
Explore the profile of Michael T Davis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
98
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis M, Anders N, Colevas A, Messick T, Rudek M
Biomed Chromatogr
. 2023 Nov;
38(2):e5775.
PMID: 37942577
EBNA1 is an Epstein Barr virus (EBV) protein expressed in all EBV-associated cancers. EBNA1 plays a critical role in the replication and maintenance of EBV episomes in latently infected cells....
2.
Challenges in developing a validated biomarker for angiogenesis inhibitors: the motesanib experience
Bass M, Yao B, Hei Y, Ye Y, Davis G, Davis M, et al.
PLoS One
. 2014 Oct;
9(10):e108048.
PMID: 25314641
Purpose: We sought to develop placental growth factor as a predictive pharmacodynamic biomarker for motesanib efficacy as first-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. Experimental Design: Placental...
3.
Davis M, Auger P, Spahr C, Patterson S
Proteomics Clin Appl
. 2010 Dec;
1(12):1545-58.
PMID: 21136654
Time-course analyses of rapidly processed serum performed in parallel by SELDI and nanoscale LC-MS/MS have revealed the temporal correlation of several literature-based disease markers with ex vivo driven events such...
4.
Bass M, Sherman S, Schlumberger M, Schlumberger M, Davis M, Kivman L, et al.
J Clin Endocrinol Metab
. 2010 Aug;
95(11):5018-27.
PMID: 20739388
Context: Antiangiogenic therapies have shown potential in the treatment of advanced thyroid cancer, but it is uncertain which patients are most likely to benefit from therapy. Objective: This prespecified exploratory...
5.
Yu W, Taylor J, Davis M, Bonilla L, Lee K, Auger P, et al.
Proteomics
. 2010 Jan;
10(6):1172-89.
PMID: 20101609
Despite recent advances in qualitative proteomics, the automatic identification of peptides with optimal sensitivity and accuracy remains a difficult goal. To address this deficiency, a novel algorithm, Multiple Search Engines,...
6.
Davis M, Auger P, Patterson S
Clin Chem
. 2009 Dec;
56(2):244-7.
PMID: 19959624
No abstract available.
7.
Johnson R, Davis M, Taylor J, Patterson S
Methods
. 2005 Feb;
35(3):223-36.
PMID: 15722219
High throughput protein analysis (i.e., proteomics) first became possible when sensitive peptide mass mapping techniques were developed, thereby allowing for the possibility of identifying and cataloging most 2D gel electrophoresis...
8.
Keire D, Wu S, Diehl D, Chew P, Ho F, Davis M, et al.
Regul Pept
. 2003 Apr;
113(1-3):115-24.
PMID: 12686470
Details of prohormone processing patterns are revealed by purification and characterization of molecular forms stored in the tissues where the hormones are expressed. Molecular forms of rat gastrin were purified...
9.
Reeve Jr J, Keire D, Coskun T, Green G, Evans C, Ho F, et al.
Regul Pept
. 2003 Apr;
113(1-3):71-7.
PMID: 12686463
The carboxyl terminal octapeptide of cholecystokinin (CCK-8) has been hypothesized to account for the bioactivity of all the molecular forms of cholecystokinin. However, the physiological relevance of CCK-58 has not...
10.
Reeve Jr J, McVey D, Bunnett N, Solomon T, Keire D, Ho F, et al.
Pancreas
. 2002 Oct;
25(3):e50-5.
PMID: 12370550
Introduction And Aims: It has been proposed that distinct tertiary structures of the C-terminus of CCK-8 and CCK-58 result in differences in stimulation of pancreatic amylase secretion. Binding of CCK-8...